211 results on '"Latremouille-Viau, Dominick"'
Search Results
2. Delayed treatment initiation of oral anticoagulants among Medicare patients with atrial fibrillation
3. Real-world experience of pediatric patients treated with peanut (Arachis hypogaea) allergen powder-dnfp
4. Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non–Small Cell Lung Cancer: A Multiregional Chart Review in the United States, Europe, and Japan
5. Real-world clinical outcomes and healthcare costs in patients with Crohn's disease treated with vedolizumab versus ustekinumab in the United States.
6. MM-359 Real-World Treatment Characteristics and Clinical Outcomes in Medicare Beneficiaries With Newly Diagnosed Multiple Myeloma (NDMM) Treated With Bortezomib in Combination With Lenalidomide and Dexamethasone (VRd)
7. CML-475 Real-World Treatment Patterns Among Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Cycling Through Multiple Tyrosine Kinase Inhibitors (TKIs) in the United States (US)
8. Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review
9. Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review
10. Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States
11. Real-world upper endoscopy utilization patterns among patients with gastroesophageal reflux disease, Barrett esophagus, and Barrett esophagus-related esophageal neoplasia in the United States
12. Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States
13. Poster: MM-359 Real-World Treatment Characteristics and Clinical Outcomes in Medicare Beneficiaries With Newly Diagnosed Multiple Myeloma (NDMM) Treated With Bortezomib in Combination With Lenalidomide and Dexamethasone (VRd)
14. Poster: CML-475 Real-World Treatment Patterns Among Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Cycling Through Multiple Tyrosine Kinase Inhibitors (TKIs) in the United States (US)
15. Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States
16. Chronic Myeloid Leukemia: Part II—Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective
17. CT-306 Evaluation of the Healthcare System Burden Associated With Intravenous Treatment for Paroxysmal Nocturnal Hemoglobinuria
18. CT-305 Real-World Clinical Outcomes in Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Eculizumab or Ravulizumab in the US: A Retrospective Claims Database Analysis
19. MDS-658 Real-World Clinical Outcomes Among Patients Untreated With Complement Inhibitors (CIs) in Paroxysmal Nocturnal Hemoglobinuria (PNH) – A Retrospective Claims Database Analysis in the United States
20. CML-205 Non-Optimal Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Tyrosine Kinase Inhibitors (TKI) in the United States: A Claims Data Analysis
21. CML-317 Asciminib After Two or More Prior Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Real-World Evaluation of Treatment Patterns and Clinical Outcomes in US Clinical Practice
22. CML-196 Asciminib After One Prior Tyrosine Kinase Inhibitor (TKI) in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): A Real-World Chart Review Study in the United States (US)
23. Real-World Clinical Outcomes Among Patients Untreated With Complement Inhibitors (CIs) in Paroxysmal Nocturnal Hemoglobinuria (PNH) – A Retrospective Claims Database Analysis in the United States
24. Asciminib After Two or More Prior Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Real-World Evaluation of Treatment Patterns and Clinical Outcomes in US Clinical Practice
25. Non-Optimal Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Tyrosine Kinase Inhibitors (TKI) in the United States: A Claims Data Analysis
26. Asciminib After One Prior Tyrosine Kinase Inhibitor (TKI) in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): A Real-World Chart Review Study in the United States (US)
27. PP01.08 Real-world outcomes of first-line anti-PD(L)1-based combination therapy for mNSCLC in Europe
28. Economic burden associated with the use of generic antiepileptic drugs in the United States
29. Poster: CML-311: Healthcare Resource Utilization and Associated Costs Among Patients with Chronic Myeloid Leukemia by Line of Therapy in the United States (US) from a Commercial Perspective
30. CML-311: Healthcare Resource Utilization and Associated Costs Among Patients with Chronic Myeloid Leukemia by Line of Therapy in the United States (US) from a Commercial Perspective
31. Health-care resource utilization associated with peanut allergy management under allergen avoidance among commercially insured individuals
32. The Impact of Drug Vintage on Patient Survival: A Patient-Level Analysis Using Quebec's Provincial Health Plan Data
33. Economic burden of peanut allergy in pediatric patients with evidence of reactions to peanuts in the United States
34. Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates
35. Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis
36. A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care
37. PP01.09 Real-world clinical outcomes after progression with anti-PD(L)1 and chemotherapy in mNSCLC in the US
38. Effectiveness of Second-Line (2L) Tyrosine Kinase Inhibitor (TKI) Therapy after Resistance or Intolerance to a Prior TKI in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP)
39. Treatment Patterns and Healthcare Resource Utilization in Patients with Multiple Myeloma and Baseline Renal Impairment
40. Real-World Treatment Patterns, Healthcare Resource Utilization and Associated Costs Among Patients with Chronic Myeloid Leukemia in Later Lines of Therapy
41. S0769 Comparative Evaluation of Treatment Outcomes in Patients With Crohn’s Disease Treated With Ustekinumab vs Vedolizumab
42. Clinical and economic burden of medicare beneficiaries with multiple myeloma and renal impairment: An observational study.
43. Psoriasis is significantly associated with lower rates of pregnancy and live births
44. Economic burden of psoriasis and obesity in patients with psoriasis in the United States
45. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution
46. Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance – the perspective of private and public payers
47. MDS-112: A SEER-Medicare Analysis of Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agent
48. CML-085: Discontinuation of Tyrosine Kinase Inhibitor (TKI) Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in US Clinical Practice Following Updates to NCCN CML Practice Guidelines
49. MDS-108: Healthcare Resource Utilization and Costs in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis
50. Discontinuation of tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia in chronic phase (CML-CP) in US clinical practice after guideline updates.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.